Key result
Bortezomib-lenalidomide-dexamethasone linked to hypersensitivity myocarditis at 19 days that resolves with corticosteroids.
Why the study?
Drug-induced myocarditis is a rare but serious complication of cancer treatments such as lenalidomide and bortezomib, requiring awareness for early diagnosis and treatment.
Does discontinuation of chemotherapy and high-dose corticosteroids improve outcomes in a patient with lenalidomide/bortezomib-induced hypersensitivity myocarditis?
Case Report (n=1)
Does discontinuation of chemotherapy and high-dose corticosteroids improve outcomes in a patient with lenalidomide/bortezomib-induced hypersensitivity myocarditis?
Highlights the rare but severe complication of hypersensitivity myocarditis associated with lenalidomide/bortezomib therapy and the importance of prompt recognition and corticosteroid treatment.
No takes yet. Share an insight, caveat, or question.
Alerts clinicians to monitor for myocarditis during bortezomib-lenalidomide-dexamethasone therapy; leaves open optimal management strategies.
Verbesselt et al. (2022) conducted a case report in Multiple myeloma (n=1). bortezomib-lenalidomide-dexamethasone was evaluated on Hypersensitivity myocarditis. A 69-year-old woman developed hypersensitivity myocarditis 19 days after initiating bortezomib-lenalidomide-dexamethasone therapy for multiple myeloma, resolving with corticosteroids.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: